741 related articles for article (PubMed ID: 11774936)
1. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
2. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Lew EA; Pisegna JR; Starr JA; Soffer EF; Forsmark C; Modlin IM; Walsh JH; Beg M; Bochenek W; Metz DC
Gastroenterology; 2000 Apr; 118(4):696-704. PubMed ID: 10734021
[TBL] [Abstract][Full Text] [Related]
4. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
5. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Pisegna JR; Martin P; McKeand W; Ohning G; Walsh JH; Paul J
Am J Gastroenterol; 1999 Oct; 94(10):2874-80. PubMed ID: 10520836
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with Zollinger-Ellison syndrome.
Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
9. Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome.
Désir B; Poitras P
Can J Gastroenterol; 2001 Dec; 15(12):795-8. PubMed ID: 11773945
[TBL] [Abstract][Full Text] [Related]
10. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
11. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of intravenously administered pantoprazole in the treatment of gastrinoma].
Modlin IM
Recenti Prog Med; 2001; 92(7-8):456-61. PubMed ID: 11475787
[TBL] [Abstract][Full Text] [Related]
13. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
14. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
Metz DC; Comer GM; Soffer E; Forsmark CE; Cryer B; Chey W; Pisegna JR
Aliment Pharmacol Ther; 2006 Feb; 23(3):437-44. PubMed ID: 16423003
[TBL] [Abstract][Full Text] [Related]
15. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
[TBL] [Abstract][Full Text] [Related]
16. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
[TBL] [Abstract][Full Text] [Related]
17. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Morocutti A; Merrouche M; Bjaaland T; Humphries T; Mignon M
Aliment Pharmacol Ther; 2006 Nov; 24(10):1439-44. PubMed ID: 17081164
[TBL] [Abstract][Full Text] [Related]
18. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
Metz DC
Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
[TBL] [Abstract][Full Text] [Related]
19. Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression.
Trépanier EF
Can J Gastroenterol; 2000 Nov; 14 Suppl D():11D-20D. PubMed ID: 11110607
[TBL] [Abstract][Full Text] [Related]
20. Protonix. First i.v. proton pump inhibitor approved.
Nursing; 2002 Feb; 32(2):18, 20. PubMed ID: 11924161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
